On October 21, 2020 Reference is made to the stock exchange announcement by Nordic Nanovector ASA (the "Company") on 23 and 30 September 2020 where the Company reported the successful completion of a private placement raising gross proceeds of approximately NOK 231 million (the "Private Placement") and that the board of directors would consider to carry out a repair offering of up to 2,285,714 new shares in the Company (the "Repair Offering") (Press release, Nordic Nanovector, OCT 21, 2020, View Source [SID1234568760]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company has decided not to proceed with the Repair Offering. Since the announcement of completion of the Private Placement, the Company’s shares have traded on the Oslo Stock Exchange, with significant trading volume, at prices close to or below the subscription price in the Private Placement of NOK 17.50. Accordingly, any shareholders wishing to neutralize the dilutive effect of the Private Placement have had the opportunity to purchase shares in the Company in the market, at prices close to or below what would have been the subscription price in a Repair Offering. In light of this, the Company has resolved not to proceed with a Repair Offering that would have resulted in additional costs for the Company.